Why the study?
The effects of inhibitor monotherapy compared with conventional DAPT in patients with chronic coronary syndromes versus ACS remain uncertain.
Does P2Y12 inhibitor-based SAPT reduce major bleeding without increasing major adverse cardiovascular and cerebral events compared to conventional DAPT in patients with chronic and acute coronary syndromes after newer-generation drug-eluting stent implantation?
Does P2Y12 inhibitor-based SAPT reduce major bleeding without increasing major adverse cardiovascular and cerebral events compared to conventional DAPT in patients with chronic and acute coronary syndromes after newer-generation drug-eluting stent implantation?
Answers are grounded in this paper and cite their sources.
P2Y12 inhibitor monotherapy after newer-generation DES implantation reduces major bleeding without increasing ischemic events compared to conventional DAPT, particularly in ACS patients.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Iglesias et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: